Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.

HealthDay News — The prevalence of post-COVID-19 condition (PCC) was 8.4% among US adults in 2023, according to a research letter published online in JAMA Network Open.

Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.

Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in north ...

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Significant changes from previous guideline include recommendation that only FSH >25 IU required for POI diagnosis.

Clinicians should identify barriers to treatment and improving clinical influenza testing, providing antiviral treatment for children with influenza-associated hospitalizations with >2 days of ...